Related Topics News -

     
 Title only   |   Print 
     
復宏漢霖HLX3902注射液於中國境內完成1期臨床研究首例患者給藥

2026-07-30T  
復宏漢霖HLX18內地臨床完成首例患者給藥

2026-07-16T  
復宏漢霖HLX37聯合HLX43用於實體瘤治療1期臨床試驗申請獲藥監局批准

2026-07-10T  
復宏漢霖HLX05-N用於mCRC 1期臨床研究完成首例患者給藥

2026-07-08T  
復宏漢霖注射用HLX48用於實體瘤治療1期臨床研究於中國完成首例患者給藥

2026-06-30T  
復宏漢霖HLX13一線治療不可切除晚期肝細胞癌I期臨床研究完成美國首例患者給藥

2026-06-26T  
復宏漢霖歐盟委員會批准斯魯利單抗新增適應症

2026-06-26T  
復宏漢霖漢倍優通過GMP符合性檢查

2026-06-17T  
億勝生物貝伐珠單抗(HLX04-O)眼科適應症III期臨床達主要研究終點

2026-06-16T  
復宏漢霖注射用HLX43聯合漢斯狀獲澳洲批准2期臨床試驗 HLX04-O 3期研究達主要研究終點

2026-06-16T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.